Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Asahi Kasei Corporation (3407.T)
Tokyo, JP
Asahi Kasei Corporation is a prominent Japanese enterprise operating globally in the manufacturing, processing, and distribution of a broad spectrum of products, primarily rooted in chemical science. Its diverse operations are strategically organized into three key business units: Material, Homes, and Health Care. Within the Material segment, the company produces a vast array of industrial and specialty chemicals, including foundational chemicals like caustic soda, nitric acid, and ammonia, alongside advanced intermediates such as acrylonitrile and styrene. This segment also encompasses a wide range of polymers, functional membranes, electronic and optical materials, and battery separators crucial for various industries. Furthermore, it offers high-performance fibers and textiles, such as cupro and nylon products, nonwoven fabrics, synthetic rubber, and elastomers. Consumer-oriented products like household items, cleaners, and packaging solutions, as well as electronic devices, also fall under this division. The Homes segment specializes in residential construction, providing a comprehensive suite of services that includes building houses and apartments, managing rental properties and condominiums, brokering used homes, and delivering remodeling solutions. It also extends financial services, such as mortgage financing and asset management, along with insurance products, supporting the entire homeowner journey. Lastly, the Health Care division focuses on developing and supplying pharmaceuticals and diagnostic reagents. It manufactures a variety of advanced medical equipment, including dialyzers, therapeutic apheresis systems, filters for biotherapeutics and virus removal, leukocyte reduction filters, and critical care devices like defibrillators and temperature management systems. Innovative technologies such as UVC LED products are also part of its offerings, contributing to advancements in health. Established in 1922, Asahi Kasei maintains its corporate headquarters in Tokyo, Japan.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +2.11% | +5.49% | -5.00% | +34.77% | +19.01% | +71.35% | +75.93% | +36.90% | +130.43% | +36.29% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 3 | 0 |
| Buy | 7 | 0 |
| Hold | 2 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Chemicals: +4.0%+1.2% Q1'26: +4.5% (vs Q1'25)
-
EPS growth Chemicals: +11.7%+19.4% ★ Q1'26: +4.7% (vs Q1'25)
-
FCF margin FCF growth · Chemicals: +41.7%+4.8% Q1'26: +7.6% (vs Q1'25)
-
EBIT margin Chemicals: +7.1%+7.5% ★ Q1'26: +7.0% (vs Q1'25)
-
ROIC Chemicals: +3.4%+6.3% ★ Q1'26: +7.7% (vs Q1'25)
-
Share dilution Chemicals: +0.0%-1.5% ★ Q1'26: -0.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Chemicals: 0.55×2.37× Q1'26: 2.35× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2015 actual |
Mar 2016 actual |
Mar 2017 actual |
Mar 2018 actual |
Mar 2019 actual |
Mar 2020 actual |
Mar 2021 actual |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 12 Rev. Ana. 12 EPS Ana. |
Mar 2027 11 Rev. Ana. 9 EPS Ana. |
Mar 2028 11 Rev. Ana. 11 EPS Ana. |
Mar 2029 3 Rev. Ana. 2 EPS Ana. |
Mar 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1.99T
est: 1.98T (+0.1%)
|
1.94T
est: 1.97T (-1.3%)
|
1.88T
est: 1.87T (+0.9%)
|
2.04T
est: 2.04T (0.0%)
|
2.17T
est: 2.18T (-0.2%)
|
2.15T
est: 2.17T (-1.0%)
|
2.11T
est: 2.09T (+0.8%)
|
2.46T
est: 2.46T (-0.1%)
|
2.73T
est: 2.71T (+0.4%)
|
2.78T
est: 2.87T (-3.0%)
|
3.04T
est: 3.04T (+0.0%)
|
3.07T
3.04T – 3.13T
+1.1% YoY
|
3.17T
3.06T – 3.27T
+3.2% YoY
|
3.26T
3.12T – 3.42T
+3.0% YoY
|
3.29T
3.24T – 3.34T
+0.8% YoY
|
3.46T
3.33T – 3.60T
+5.2% YoY
|
| EBITDA |
253.31B
est: 212.89B (+19.0%)
|
274.84B
est: 211.08B (+30.2%)
|
268.42B
est: 200.32B (+34.0%)
|
311.94B
est: 219.16B (+42.3%)
|
313.63B
est: 233.42B (+34.4%)
|
295.57B
est: 233.18B (+26.8%)
|
305.08B
est: 224.28B (+36.0%)
|
350.78B
est: 264.31B (+32.7%)
|
305.00B
est: 291.34B (+4.7%)
|
322.94B
est: 416.10B (-22.4%)
|
398.03B
est: 440.23B (-9.6%)
|
445.03B
440.53B – 454.36B
+1.1% YoY
|
459.28B
444.20B – 474.52B
+3.2% YoY
|
472.93B
453.04B – 495.57B
+3.0% YoY
|
476.90B
469.88B – 483.92B
+0.8% YoY
|
501.85B
483.02B – 522.27B
+5.2% YoY
|
| EBIT |
157.93B
est: 87.84B (+79.8%)
|
165.20B
est: 87.09B (+89.7%)
|
159.23B
est: 82.65B (+92.7%)
|
198.48B
est: 90.42B (+119.5%)
|
209.59B
est: 96.31B (+117.6%)
|
177.26B
est: 96.21B (+84.2%)
|
171.81B
est: 92.54B (+85.7%)
|
202.65B
est: 109.05B (+85.8%)
|
127.72B
est: 120.20B (+6.3%)
|
140.75B
est: 227.57B (-38.2%)
|
211.92B
est: 240.76B (-12.0%)
|
243.39B
240.93B – 248.49B
+1.1% YoY
|
251.18B
242.93B – 259.52B
+3.2% YoY
|
258.65B
247.77B – 271.03B
+3.0% YoY
|
260.82B
256.98B – 264.66B
+0.8% YoY
|
274.47B
264.16B – 285.63B
+5.2% YoY
|
| Net Income |
105.65B
est: 103.84B (+1.7%)
|
91.75B
est: 90.82B (+1.0%)
|
115.00B
est: 107.00B (+7.5%)
|
170.25B
est: 164.21B (+3.7%)
|
147.51B
est: 146.21B (+0.9%)
|
103.93B
est: 126.64B (-17.9%)
|
79.77B
est: 78.42B (+1.7%)
|
161.88B
est: 170.95B (-5.3%)
|
-91.95B
est: -100.71B (+8.7%)
|
43.81B
est: 68.31B (-35.9%)
|
135.00B
est: 120.62B (+11.9%)
|
139.94B
122.69B – 157.19B
+16.0% YoY
|
161.54B
151.54B – 181.31B
+15.4% YoY
|
181.44B
160.91B – 217.16B
+12.3% YoY
|
222.75B
202.14B – 224.40B
+22.8% YoY
|
223.18B
212.29B – 234.98B
+0.2% YoY
|
| SGA |
331.23B
est: 430.58B (-23.1%)
|
360.02B
est: 426.92B (-15.7%)
|
368.03B
est: 405.15B (-9.2%)
|
388.63B
est: 443.24B (-12.3%)
|
416.04B
est: 472.10B (-11.9%)
|
435.53B
est: 471.61B (-7.7%)
|
447.37B
est: 453.61B (-1.4%)
|
495.63B
est: 534.57B (-7.3%)
|
572.03B
est: 589.23B (-2.9%)
|
601.87B
est: 616.02B (-2.3%)
|
586.30B
est: 651.75B (-10.0%)
|
658.85B
652.19B – 672.67B
+1.1% YoY
|
679.94B
657.62B – 702.51B
+3.2% YoY
|
700.16B
670.71B – 733.67B
+3.0% YoY
|
706.04B
695.65B – 716.43B
+0.8% YoY
|
742.98B
715.09B – 773.20B
+5.2% YoY
|
| EPS |
75.62
est: 75.34 (+0.4%)
|
65.69
est: 65.89 (-0.3%)
|
82.34
est: 77.63 (+6.1%)
|
121.93
est: 119.14 (+2.3%)
|
105.66
est: 106.08 (-0.4%)
|
74.85
est: 91.88 (-18.5%)
|
57.49
est: 56.89 (+1.1%)
|
116.68
est: 124.03 (-5.9%)
|
-66.30
est: -73.22 (+9.4%)
|
31.60
est: 49.28 (-35.9%)
|
97.94
est: 84.58 (+15.8%)
|
106.35
90.38 – 115.79
+25.7% YoY
|
121.56
111.63 – 133.56
+14.3% YoY
|
136.81
118.53 – 159.97
+12.5% YoY
|
157.10
148.90 – 165.30
+14.8% YoY
|
164.40
156.38 – 173.09
+4.6% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-18 | A | 4/5 | 5/5 | 4/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-15 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-14 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-13 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-12 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-11 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-08 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-07 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-01 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-30 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-28 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-27 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-24 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-23 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-22 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-21 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-20 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-17 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-16 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-15 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Koshiro Kudo | President, Presidential Executive Officer for Material Business Sector & Representative Director | 137M | male |
| Hideki Tsutsumi | Senior Executive Officer and Executive Officer for Procurement & Logistics | — | male |
| Hideyuki Yamagishi | Primary Executive Officer | — | — |
| Jonathan A. Rennert | Senior Executive Officer | — | male |
| Nobuhiro Yamaguchi | Lead Ex. Officer and Ex. Officer for General Affairs, Legal, Corporate Comm, Risk Mgt & Compliance | — | — |
| Richard A. Packer | Vice-Presidential Executive Officer & Executive OfficerCorporate Initiatives | — | male |
| Satoshi Nishikawa | Senior Executive Officer & Executive Officer for HR | — | — |
| Shuichi Sakamoto | Primary Executive Officer for Health Care Business Sector (Joint) | — | male |
| Futoshi Hamamoto | General Manager of Investor Relations | — | male |
| Toshiyasu Horie | Chief Financial Officer, Executive Officer of Strategy, Accounting, Finance & IR, Primary EO and Representative Director | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 3407.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
